Synlogic, Inc. (SYBX) |
| 1.05 0 (0%) 10-26 16:00 |
| Open: | 0.965 |
| High: | 1.05 |
| Low: | 0.965 |
| Volume: | 1,099 |
| Market Cap: | 13(M) |
| PE Ratio: | -17.5 |
| Exchange: | Other OTC |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 1.19 |
| Resistance 1: | 1.10 |
| Pivot price: | 1.06 |
| Support 1: | 0.96 |
| Support 2: | 0.80 |
| 52w High: | 1.87 |
| 52w Low: | 0.54 |
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
Financials
| EPS | -0.060 |
| Book Value | 1.030 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -15.6 |
| Return on Equity (ttm) | -5.3 |
Company news
Fri, 23 Oct 2026
Synlogic, Inc. Estimates – OTC:SYBX - TradingView
Tue, 11 Aug 2026
SYNLOGIC, INC. Q2 2026: Revenue $0 Net loss $(0.54M) — 10-Q Summary - TradingView
Wed, 29 Jul 2026
Caldera merges with Synlogic to fund Phase II trials of TL1A × IL-23p19 bispecific for IBD - AllSci
Wed, 29 Jul 2026
Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement - Business Wire
Thu, 22 Jan 2026
Synlogic (OTCPK:SYBX) - Stock Analysis - Simply Wall Street
Sat, 10 Feb 2024
Synlogic Announces Plan to Cease Operations and Reduce Its Workforce by More Than 90% - SynBioBeta
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
